What is STRATEOS?
Strateos operates at the intersection of robotics, software engineering, and biotechnology. By providing a Cloud Lab Automation-as-a-Service platform, the company enables researchers to design, execute, and analyze complex experiments remotely. This paradigm shift away from traditional, manual laboratory workflows allows for unprecedented efficiency in drug discovery and biological research. Strateos effectively democratizes access to high-end instrumentation, ensuring that data-driven insights are generated with greater precision and lower overhead than conventional methods allow. The company's architecture is designed to integrate seamlessly with existing computational workflows, positioning it as an essential partner for modern biopharma and academic institutions.
How much funding has STRATEOS raised?
STRATEOS has raised a total of $64.6M across 2 funding rounds:
Series A
$8.5M
Series B
$56.1M
Series A (2015): $8.5M with participation from IA Ventures, Y Combinator, UpHonest Capital, AME Cloud Ventures, MITS Fund, Wei Guo, DCVC, Silicon Valley Bank, Holtzbrinck Digital, and Paul Buchheit
Series B (2021): $56.1M led by Black Diamond Ventures, DCVC Management, Lux Capital, Ally Bridge Group, and Lilly
Key Investors in STRATEOS
DCVC Management
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling some of the world's most challenging problems, focusing on leveraging artificial intelligence to unlock potential across biotechnology and agriculture.
Lux Capital
Lux Capital is a venture capital firm that raises dedicated funds to invest in early-stage and growth-stage companies at the intersection of science and technology, backing founders in frontier areas such as robotics and biotechnology.
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm that specializes in high-impact life science innovation, operating with a mission to generate superior risk-adjusted returns while addressing unmet medical needs.
What's next for STRATEOS?
With the successful closure of its latest financing round, Strateos is well-positioned to accelerate the deployment of its next-generation automation capabilities. The strategic focus will likely center on expanding the breadth of its robotic laboratory services and enhancing the underlying software stack to support more complex, multi-modal experimental designs. As the life sciences industry continues to embrace digital transformation, Strateos is poised to capture significant market share by serving as the backbone for automated discovery. Future growth will likely involve deepening partnerships with global pharmaceutical entities and scaling its infrastructure to meet the increasing demand for high-throughput, reproducible scientific data.
See full STRATEOS company page
